Hana Pharm Statistics
Total Valuation
Hana Pharm has a market cap or net worth of KRW 194.08 billion.
Market Cap | 194.08B |
Enterprise Value | n/a |
Important Dates
The next estimated earnings date is Friday, March 14, 2025.
Earnings Date | Mar 14, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Hana Pharm has 17.77 million shares outstanding.
Current Share Class | n/a |
Shares Outstanding | 17.77M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 57.71% |
Owned by Institutions (%) | 0.65% |
Float | 7.06M |
Valuation Ratios
The trailing PE ratio is 4.87.
PE Ratio | 4.87 |
Forward PE | n/a |
PS Ratio | 0.85 |
PB Ratio | 1.46 |
P/TBV Ratio | 2.50 |
P/FCF Ratio | 12.78 |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.63, with a Debt / Equity ratio of 0.36.
Current Ratio | 1.63 |
Quick Ratio | 1.22 |
Debt / Equity | 0.36 |
Debt / EBITDA | 0.82 |
Debt / FCF | 1.91 |
Interest Coverage | 30.47 |
Financial Efficiency
Return on equity (ROE) is 35.53% and return on invested capital (ROIC) is 20.21%.
Return on Equity (ROE) | 35.53% |
Return on Assets (ROA) | 15.52% |
Return on Capital (ROIC) | 20.21% |
Revenue Per Employee | n/a |
Profits Per Employee | n/a |
Employee Count | n/a |
Asset Turnover | 1.09 |
Inventory Turnover | 2.43 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -21.78% in the last 52 weeks. The beta is 0.47, so Hana Pharm's price volatility has been lower than the market average.
Beta (5Y) | 0.47 |
52-Week Price Change | -21.78% |
50-Day Moving Average | 10,975.20 |
200-Day Moving Average | 12,232.95 |
Relative Strength Index (RSI) | 51.35 |
Average Volume (20 Days) | 24,389 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Hana Pharm had revenue of KRW 139.33 billion and earned 24.30 billion in profits. Earnings per share was 2,243.00.
Revenue | 139.33B |
Gross Profit | 94.00B |
Operating Income | 31.81B |
Pretax Income | 30.96B |
Net Income | 24.30B |
EBITDA | 35.33B |
EBIT | 31.81B |
Earnings Per Share (EPS) | 2,243.00 |
Balance Sheet
The company has 16.49 billion in cash and 29.05 billion in debt, giving a net cash position of -12.56 billion or -706.42 per share.
Cash & Cash Equivalents | 16.49B |
Total Debt | 29.05B |
Net Cash | -12.56B |
Net Cash Per Share | -706.42 |
Equity (Book Value) | 81.30B |
Book Value Per Share | 7,469.67 |
Working Capital | 30.69B |
Cash Flow
In the last 12 months, operating cash flow was 25.38 billion and capital expenditures -10.19 billion, giving a free cash flow of 15.19 billion.
Operating Cash Flow | 25.38B |
Capital Expenditures | -10.19B |
Free Cash Flow | 15.19B |
FCF Per Share | 854.50 |
Margins
Gross margin is 67.47%, with operating and profit margins of 22.83% and 17.44%.
Gross Margin | 67.47% |
Operating Margin | 22.83% |
Pretax Margin | 22.22% |
Profit Margin | 17.44% |
EBITDA Margin | 25.36% |
EBIT Margin | 22.83% |
FCF Margin | 10.90% |
Dividends & Yields
Hana Pharm does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | 4.21% |
Buyback Yield | n/a |
Shareholder Yield | n/a |
Earnings Yield | 20.54% |
FCF Yield | 7.83% |
Stock Splits
The last stock split was on April 28, 2021. It was a forward split with a ratio of 1.1000011.
Last Split Date | Apr 28, 2021 |
Split Type | Forward |
Split Ratio | 1.1000011 |
Scores
Hana Pharm has an Altman Z-Score of 2.67. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 2.67 |
Piotroski F-Score | n/a |